ReviewInternational journal of molecular sciences2026
Calcineurin Inhibitors and Male Fertility in Renal Transplant Recipients: A Comprehensive Review of Molecular Pathomechanisms and Reproductive Toxicity of Cyclosporine A and Tacrolimus.
Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
This comprehensive review provides a detailed organ-resolved and translational synthesis of the effects of calcineurin inhibitors, such as cyclosporine A (CsA) and tacrolimus (FK506), on male reproductive function following kidney transplantation. This review summarises experimental and clinical evidence relating to the testes, epididymis, accessory glands, the hypothalamic-pituitary-gonadal axis and semen parameters. It also considers molecular mechanisms, clinical outcomes and transplant-related confounding factors. Experimental evidence indicates that calcineurin inhibitors can cause testicular injury in a dose- and duration-dependent manner, resulting in seminiferous epithelium disorganisation, impaired Sertoli-germ cell interactions, Leydig cell atrophy, reduced testosterone synthesis, and reduced sperm count and motility. In animal models, CsA appears to induce more pronounced histological and steroidogenic disruption. In contrast, murine studies suggest that FK506 primarily exerts molecular alterations on post-testicular sperm maturation. Proposed preclinical mechanisms include oxidative stress, mitochondrial dysfunction, apoptosis and microvascular remodelling. However, their direct role in human recipients remains to be fully verified. Clinical findings demonstrated that successful transplantation often improves pre-existing uremic hypogonadism, and semen quality usually recovers within one to two years, particularly with stable graft function and lower calcineurin inhibitor exposure. However, persistent abnormalities can occur, and outcomes are confounded by, among others, renal function or combination therapy. It is important to distinguish direct calcineurin inhibitor-induced reproductive toxicity from the confounding effects of chronic kidney disease, prior dialysis exposure, and glucocorticoid use, as these transplant-related factors significantly modulate gonadal function independently of calcineurin inhibition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.